A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Key facts
- Where
- Shreveport, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07867938, who can take part
Where in United States
- Care Access Research Llc (Site 2725)Shreveport, United StatesContact: Study CoordinatorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT07867938EU 2025-524270-42-00
- Record updated
- 9 November 2026
- Original description
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).Read full original descriptionShow less
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).
This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.
Inclusion: The main inclusion criteria include but are not limited to the following:; Has a diagnosis of sarcoidosis of ≥6 months before Screening confirmed by tissue biopsy; Has lung parenchymal involvement consistent with pulmonary sarcoidosis (PS) by chest X-ray or chest high-resolution computed tomography (HRCT) either via historical evidence or at Screening; Has active PS within 3 months before Screening.
Exclusion: Is receiving treatment for pulmonary hypertension; Has a history of fungal respiratory infection within 12 months before screening without documentation of completed treatment; Is a current smoker defined as smoking or vaping of inhaled preparations of nicotine, tobacco, or cannabis preparations within 6 months before Screening; Has cardiac, ocular, neurosarcoidosis, or other manifestations of sarcoidosis that requires systemic treatment that may interfere with protocol specifications, or has a clinically significant electrocardiogram abnormality that requires evaluation or intervention; Has a diagnosis of or currently has a clinical presentation consistent with Löfgren syndrome; Has active tuberculosis (TB) or history of active TB; Has any condition that may interfere with the ability to adhere to oral corticosteroid therapy or taper; Has a history of cancer and is disease free for <5 years; The main exclusion criteria include but are not limited to the following:.